Home > Insider Trading > Filing (0000899243-18-007983)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1724521	Arcus Biosciences Inc.	RCUS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1206977	E Kathryn Falberg	C/O Arcus Biosciences, Inc. 3928 Point Eden Way Hayward CA 94545		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-03-19	17,106	$0.00	17,106	No	4	C	Indirect	By Trust
Common Stock	Acquisiton	2018-03-19	30,000	$15.00	80,504	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Trust
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Preferred Stock	Disposition	2018-03-19	17,106	$0.00	17,106	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The total represents shares received upon conversion of shares of Series C Convertible Preferred Stock.
The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
Represents shares purchased in the Issuer's initial public offering.
The total includes 25,252 shares of Common Stock purchased by the Reporting Person on September 21, 2017 for $2.58 per share pursuant to the exercise of an option granted on September 19, 2017 and an additional 25,252 shares of Common Stock purchased on January 25, 2018 for $5.39 per share pursuant to the exercise of a separate option granted on January 4, 2018.
Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.